Andrew Kraft to Prostatic Neoplasms
This is a "connection" page, showing publications Andrew Kraft has written about Prostatic Neoplasms.
Connection Strength
2.595
-
The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nat Commun. 2021 12 21; 12(1):7349.
Score: 0.495
-
Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1. Cancer Res. 2013 Jun 01; 73(11):3402-11.
Score: 0.271
-
Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737. Cancer Res. 2012 Jan 01; 72(1):294-303.
Score: 0.246
-
Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade. Cancer Biol Ther. 2011 Jul 15; 12(2):119-24.
Score: 0.240
-
p53-dependent induction of prostate cancer cell senescence by the PIM1 protein kinase. Mol Cancer Res. 2010 Aug; 8(8):1126-41.
Score: 0.224
-
Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res. 2005 Aug; 3(8):443-51.
Score: 0.159
-
Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem. 2001 Apr 06; 276(14):10767-74.
Score: 0.116
-
PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth. Mol Oncol. 2020 05; 14(5):974-990.
Score: 0.110
-
Inhibition of caspases by cytokine response modifier A blocks androgen ablation-mediated prostate cancer cell death in vivo. Cancer Res. 1998 Feb 15; 58(4):834-9.
Score: 0.095
-
Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc. Prostate. 1998 Feb 15; 34(3):175-81.
Score: 0.095
-
PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species. Mol Cancer Ther. 2016 07; 15(7):1637-47.
Score: 0.084
-
Regulation of prostate stromal fibroblasts by the PIM1 protein kinase. Cell Signal. 2015 Jan; 27(1):135-46.
Score: 0.075
-
Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma. Clin Genitourin Cancer. 2014 Apr; 12(2):80-6.
Score: 0.071
-
A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy. Anticancer Drugs. 2013 Aug; 24(7):743-53.
Score: 0.069
-
Collaboration of Kras and androgen receptor signaling stimulates EZH2 expression and tumor-propagating cells in prostate cancer. Cancer Res. 2012 Sep 15; 72(18):4672-81.
Score: 0.064
-
Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells. Mol Cancer Ther. 2009 Jun; 8(6):1473-83.
Score: 0.052
-
The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther. 2005 Mar; 4(3):443-9.
Score: 0.039
-
Overexpression of the oncogenic kinase Pim-1 leads to genomic instability. Cancer Res. 2003 Dec 01; 63(23):8079-84.
Score: 0.035
-
Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Clin Cancer Res. 2000 Nov; 6(11):4205-8.
Score: 0.029
-
Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells. Cell Death Differ. 1999 Feb; 6(2):175-82.
Score: 0.025